Coeptis Therapeutics Holdings IncNASDAQ COEP Stock Report

Coeptis Therapeutics Holdings, Inc. engages in the development of innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer. The firm's product portfolio and rights are highlighted by a universal, multi-antigen chimeric antigen receptor (CAR)-T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells (a type of immune cell) are genetically engineered to recognize cancer cells to target and destroy them. Its CAR T therapies are revolutionizing the treatment of many blood cancers, including B cell leukemias and lymphomas by targeting specific proteins found in these cancers.